What Are the Best Weight Loss Pills? Comparing GLP-1 Tablets, Mysimba & Orlistat

Key Takeaways

Oral GLP-1 tablets lead clinical efficacy: the 25mg Wegovy pill averages 14–17% weight loss and Foundayo averages 11–12%.
Orlistat works locally in the gut to block ~25–30% of dietary fat without entering the bloodstream, while naltrexone-bupropion targets brain reward cravings.
Matching the medication mechanism to your primary barrier — persistent appetite, emotional cravings, or needle avoidance — produces the strongest adherence.

While weekly GLP-1 injections dominated obesity medicine over the past five years, clinically proven weight loss tablets now give needle-averse patients genuine metabolic options. Today’s four evidence-backed oral medications work through three distinct biological mechanisms.

Side-by-side comparison of licensed weight loss tablets

Feature	Wegovy Pill	Foundayo	Mysimba (Contrave)	Orlistat (Xenical / Alli)
Active ingredient	Semaglutide (oral)	Orforglipron	Naltrexone + Bupropion	Orlistat (60mg / 120mg)
Mechanism	GLP-1 appetite & satiety agonist	Small-molecule GLP-1 agonist	Hypothalamic & reward craving blocker	Intestinal lipase (fat) blocker
Average weight loss	14%–17% (1)	11%–12% (6)	~5%–9% (4)	~5%–10% (3)
Daily schedule	Once daily (fasted morning + ≤120mL water)	Once daily (any time, with/without food)	Twice daily (up to 4 tablets/day)	Up to 3x daily with fat-containing meals
Main side effects	Nausea, vomiting, constipation	Nausea, diarrhea, constipation	Nausea, dry mouth, headache, insomnia	Oily stools & urgency if meal >15g fat

How to choose the right tablet with a clinician

Choose an oral GLP-1 (Wegovy pill or Foundayo) if persistent hunger, large portions, and constant food noise are your biggest obstacles and you meet clinical BMI criteria (≥30, or ≥27 with a weight-related condition).
Choose Naltrexone-Bupropion if reward-driven snacking and cravings predominate and you have well-controlled blood pressure and no seizure or opioid use history (4,5).
Choose Orlistat if you prefer a non-systemic gut-acting capsule alongside a structured low-fat diet (3).

Start your online medical evaluation to review prescription tablet and injectable GLP-1 options with a licensed clinician.

References

Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025;393(11):1077–87.
Orlistat 120mg Capsules Summary of Product Characteristics. Electronic Medicines Compendium; 2025.
European Medicines Agency. Mysimba (naltrexone/bupropion) EPAR Product Information.
Wharton S, Aronne LJ, et al. Orforglipron for Obesity Treatment. N Engl J Med. 2025.

Medical Editorial Review: Reviewed by the Amble Clinical Editorial Team. This article is for educational purposes only and does not replace an individualized consultation with a licensed healthcare professional.